Swissmedic Approves Enhertu® for Extended Therapeutic Indications

Swissmedic has granted authorization for the extension of therapeutic indications for Enhertu® as of November 28,…

Temporary Authorization Alert: Ringerfundin B. Braun Infusion Solution Distribution Update

Swissmedic, the Swiss Agency for Therapeutic Products, has granted a temporary approval for the distribution of…

Swissmedic Spotlights Personnel Roles: Essential Update for Teams

On November 28, 2025, Swissmedic released details regarding changes in personnel requirements within its Abteilung Personal…

Swissmedic Announces HR Business Partner Opening: A Strategic Role in Regulatory Support

Swissmedic, the Swiss Agency for Therapeutic Products, has announced an exciting job opportunity for an HR…

Temporary Authorization for Ringerlactat B. Braun Infusion Solution in German Packaging

Swissmedic announces a temporary distribution authorization for Ringerlactat B. Braun Infusion Solution packaged in German labeling.…

Swissmedic Opens Access to Swissdamed UDI Devices Playground

Swissmedic has announced the release of the Swissdamed UDI Devices Playground, an online tool designed to…

Urgent Swissmedic Recall: Specific Batch of Azelastin-Fluticason-Mepha Nasal Spray Withdrawn

On November 27, 2025, Swissmedic announced an immediate recall of batch number 100062289 of Azelastin-Fluticason-Mepha Nasal…

Urgent Swissmedic Batch Recall: Lexotanil 3mg Tablets

On 26 November 2025, Swissmedic issued an official notice regarding the immediate recall of batch 1653102…

Swissmedic Grants Initial Authorisation for Tepezza®: Key Implications for Regulatory Teams

Swissmedic announces the first authorisation of Tepezza®. This development is significant for quality, clinical, and regulatory…

Swissmedic Authorizes Temporary Distribution of Glucose 5% Infusion Solution in German Packaging

Swissmedic has announced a temporary approval for the distribution of Glucose 5% B. Braun Infusionslösung in…